At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 614 enrolled
Drug / intervention
GW642444M +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma
In Brief
A Phase 2 clinical trial evaluating GW642444M and Placebo for Asthma. Completed, enrolled 614 participants across 89 sites in 16 countries.
Detailed Summary
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Belgium, Canada, Chile, France, Germany, Netherlands, Peru, Philippines, Poland, Russia, South Africa, South Korea, Sweden, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedJan 24, 2008
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.4 years ago
Interventions
GW642444Mdrug
GW642444M
Placebodrug
Placebo mulit-dose dry powder inhaler